CA2988983A1 - Mct4 inhibitors for treating disease - Google Patents
Mct4 inhibitors for treating diseaseInfo
- Publication number
- CA2988983A1 CA2988983A1 CA2988983A CA2988983A CA2988983A1 CA 2988983 A1 CA2988983 A1 CA 2988983A1 CA 2988983 A CA2988983 A CA 2988983A CA 2988983 A CA2988983 A CA 2988983A CA 2988983 A1 CA2988983 A1 CA 2988983A1
- Authority
- CA
- Canada
- Prior art keywords
- recited
- chosen
- compound
- cancer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174685P | 2015-06-12 | 2015-06-12 | |
| US62/174,685 | 2015-06-12 | ||
| PCT/US2016/037213 WO2016201426A1 (en) | 2015-06-12 | 2016-06-13 | Mct4 inhibitors for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2988983A1 true CA2988983A1 (en) | 2016-12-15 |
Family
ID=57504734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988983A Pending CA2988983A1 (en) | 2015-06-12 | 2016-06-13 | Mct4 inhibitors for treating disease |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US10202350B2 (enExample) |
| EP (2) | EP3942934A1 (enExample) |
| JP (2) | JP6944442B2 (enExample) |
| KR (1) | KR102653599B1 (enExample) |
| CN (1) | CN107635404B (enExample) |
| AU (2) | AU2016277126A1 (enExample) |
| BR (1) | BR112017026535B1 (enExample) |
| CA (1) | CA2988983A1 (enExample) |
| ES (1) | ES2894919T3 (enExample) |
| IL (2) | IL256206A (enExample) |
| WO (1) | WO2016201426A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016277126A1 (en) | 2015-06-12 | 2017-12-14 | Vettore, LLC | MCT4 inhibitors for treating disease |
| BR112019011825A2 (pt) | 2016-12-12 | 2019-10-22 | Vettore, LLC | composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente |
| WO2020033019A2 (en) | 2018-04-25 | 2020-02-13 | Charles R. Drew University Of Medicine And Science | Novel mct4 inhibitors and uses thereof |
| TWI823932B (zh) * | 2018-05-11 | 2023-12-01 | 中國大陸商迪哲（江蘇）醫藥有限公司 | 三唑并嘧啶化合物及其在治療癌症中之用途 |
| AR117469A1 (es) | 2018-12-21 | 2021-08-11 | Merck Patent Gmbh | Derivados de alquino disustituidos |
| WO2020234454A1 (en) | 2019-05-23 | 2020-11-26 | Deutsches Krebsforschungszentrum | Combination treatment of cancer targeting energy metabolism and intracellular ph |
| US20210214731A1 (en) * | 2019-10-25 | 2021-07-15 | President And Fellows Of Harvard College | Methods for treating cancer |
| WO2022243574A1 (en) * | 2021-05-21 | 2022-11-24 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use |
| CN113929627A (zh) * | 2021-10-19 | 2022-01-14 | 吕梁学院 | 一种宾达利的合成方法 |
| CN113845476B (zh) * | 2021-11-08 | 2024-04-30 | 中国药科大学 | 一种喹诺酮衍生物及其制备方法和用途 |
| EP4568953A4 (en) * | 2022-08-10 | 2026-05-20 | Vettore Llc | PROCESSES AND METHODS FOR PREPARING MCT4 INHIBITORS |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1052111B (it) | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
| US5078780A (en) | 1986-10-22 | 1992-01-07 | Ciba-Geigy Corporation | 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| IT1293795B1 (it) | 1997-07-28 | 1999-03-10 | Angelini Ricerche Spa | Farmaco attivo nel ridurre la produzione di proteina mcp-1 |
| WO2005054852A1 (en) * | 2003-11-21 | 2005-06-16 | Astrazeneca Ab | Screening method |
| EP2465850B1 (en) * | 2006-02-28 | 2016-11-23 | Dart Neuroscience (Cayman) Ltd | Therapeutic compounds |
| TWI339205B (en) | 2006-10-02 | 2011-03-21 | Nat Health Research Institutes | Pyrazole compounds and pharmaceutical composition |
| DK2254869T3 (en) | 2008-03-07 | 2017-09-04 | Acraf | 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40 |
| CN102093341B (zh) | 2009-12-10 | 2013-07-24 | 天津药物研究院 | 吲哚环取代的吡唑羧酸类内皮素受体拮抗剂及其制备方法和用途 |
| WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| US9296728B2 (en) * | 2012-01-20 | 2016-03-29 | Regents Of The University Of Minnesota | Therapeutic compounds |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| DK2882715T3 (en) * | 2012-05-18 | 2017-02-13 | Sanofi Sa | PYRAZOL DERIVATIVES AND USE THEREOF AS LPAR5 ANTAGONISTS |
| PE20151140A1 (es) | 2012-08-16 | 2015-08-07 | Janssen Pharmaceutica Nv | Pirazoles sustituidos como bloqueadores del canal de calcio tipo n |
| EP3004073A1 (en) | 2013-06-07 | 2016-04-13 | Université catholique de Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
| CA2949936C (en) | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| DE202015003905U1 (de) | 2015-06-05 | 2016-09-12 | Rudolf King | Methode zur Übermittlung und Differenzierung von Verfassungszuständen während und nach Auslösen eines persönlichen Notfallsystems oder Systems zur Mitteilung an ein soziales Notfallsystem oder Systems zur Mitteilung an ein soziales Notfall-Netzwerk |
| US20160362056A1 (en) | 2015-06-11 | 2016-12-15 | Cequent Performance Products Inc. | Roof rack crossbar assembly |
| AU2016277126A1 (en) | 2015-06-12 | 2017-12-14 | Vettore, LLC | MCT4 inhibitors for treating disease |
| BR112019011825A2 (pt) | 2016-12-12 | 2019-10-22 | Vettore, LLC | composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente |
-
2016
- 2016-06-13 AU AU2016277126A patent/AU2016277126A1/en not_active Abandoned
- 2016-06-13 ES ES16808515T patent/ES2894919T3/es active Active
- 2016-06-13 BR BR112017026535-4A patent/BR112017026535B1/pt active IP Right Grant
- 2016-06-13 EP EP21191357.9A patent/EP3942934A1/en active Pending
- 2016-06-13 CN CN201680034104.1A patent/CN107635404B/zh active Active
- 2016-06-13 JP JP2018516405A patent/JP6944442B2/ja active Active
- 2016-06-13 EP EP16808515.7A patent/EP3307068B1/en active Active
- 2016-06-13 CA CA2988983A patent/CA2988983A1/en active Pending
- 2016-06-13 WO PCT/US2016/037213 patent/WO2016201426A1/en not_active Ceased
- 2016-06-13 US US15/180,623 patent/US10202350B2/en active Active
- 2016-06-13 KR KR1020187000674A patent/KR102653599B1/ko active Active
-
2017
- 2017-12-10 IL IL256206A patent/IL256206A/en unknown
-
2018
- 2018-12-17 US US16/222,964 patent/US20190112274A1/en not_active Abandoned
-
2020
- 2020-09-23 US US17/030,243 patent/US11155522B2/en active Active
- 2020-10-22 IL IL278247A patent/IL278247B/en unknown
-
2021
- 2021-02-12 AU AU2021200919A patent/AU2021200919B2/en active Active
- 2021-06-22 JP JP2021102860A patent/JP2021152056A/ja active Pending
- 2021-09-22 US US17/481,660 patent/US11724989B2/en active Active
-
2023
- 2023-06-19 US US18/337,313 patent/US12187682B2/en active Active
-
2024
- 2024-11-25 US US18/958,610 patent/US20250257039A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018516994A (ja) | 2018-06-28 |
| HK1253239A1 (en) | 2019-06-14 |
| US12187682B2 (en) | 2025-01-07 |
| AU2016277126A1 (en) | 2017-12-14 |
| CN107635404B (zh) | 2021-09-28 |
| EP3307068B1 (en) | 2021-08-25 |
| WO2016201426A1 (en) | 2016-12-15 |
| JP6944442B2 (ja) | 2021-10-06 |
| NZ738078A (en) | 2021-11-26 |
| EP3307068A4 (en) | 2018-12-26 |
| KR102653599B1 (ko) | 2024-04-01 |
| ES2894919T3 (es) | 2022-02-16 |
| BR112017026535A2 (pt) | 2018-08-14 |
| CN107635404A (zh) | 2018-01-26 |
| IL278247B (en) | 2021-12-01 |
| US20220251045A1 (en) | 2022-08-11 |
| US20250257039A1 (en) | 2025-08-14 |
| AU2021200919B2 (en) | 2022-06-30 |
| US20210009524A1 (en) | 2021-01-14 |
| EP3307068A1 (en) | 2018-04-18 |
| IL256206A (en) | 2018-02-28 |
| BR112017026535B1 (pt) | 2023-12-19 |
| AU2021200919A1 (en) | 2021-03-04 |
| US11724989B2 (en) | 2023-08-15 |
| US11155522B2 (en) | 2021-10-26 |
| EP3942934A1 (en) | 2022-01-26 |
| JP2021152056A (ja) | 2021-09-30 |
| KR20180012852A (ko) | 2018-02-06 |
| US20160362378A1 (en) | 2016-12-15 |
| US20240101518A1 (en) | 2024-03-28 |
| US20190112274A1 (en) | 2019-04-18 |
| US10202350B2 (en) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12187682B2 (en) | MCT4 inhibitors for treating disease | |
| EP3551625B1 (en) | Heterocyclic inhibitors of mct4 | |
| CA2912156C (en) | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace) | |
| US20260132138A1 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| HK40066026A (en) | Mct4 inhibitors for treating disease | |
| HK1253239B (en) | Mct4 inhibitors for treating disease | |
| NZ738078B2 (en) | Mct4 inhibitors for treating disease | |
| HK40117469A (en) | Heterocyclic inhibitors of mct4 | |
| RU2771875C2 (ru) | Гетероциклические ингибиторы МСТ4 | |
| HK40015139A (en) | Heterocyclic inhibitors of mct4 | |
| HK40015139B (en) | Heterocyclic inhibitors of mct4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210604 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED Effective date: 20241205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250527 Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT Effective date: 20250527 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250527 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250527 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250606 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250606 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251218 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251219 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260413 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20260413 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260605 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260605 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260609 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260609 |